Daiichi Sankyo Co Ltd
XMUN:D4S
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Daiichi Sankyo Co Ltd
XMUN:D4S
|
JP |
|
B
|
Berkshire Hathaway Inc
SWB:BRH
|
US |
|
Stewart Information Services Corp
NYSE:STC
|
US |
|
Moderna Inc
NASDAQ:MRNA
|
US |
|
M
|
Manhattan Associates Inc
F:MHT
|
US |
|
T
|
Trinity Ltd
HKEX:891
|
HK |
|
A
|
AGC Inc
XMUN:SHJ
|
JP |
|
Leonteq AG
SIX:LEON
|
CH |
|
B
|
BNP Paribas SA
LSE:0HB5
|
FR |
|
Hangzhou Heatwell Electric Heating Technology Co Ltd
SSE:603075
|
CN |
|
Distribuidora Internacional de Alimentacion SA
F:DI6
|
ES |
|
Capricor Therapeutics Inc
NASDAQ:CAPR
|
US |
|
Aneka Tambang Tbk PT
IDX:ANTM
|
ID |
Daiichi Sankyo Co Ltd
Daiichi Sankyo is a Japanese pharmaceutical company that discovers, develops, manufactures, and sells prescription medicines. Its business is built around branded drugs used by doctors and hospitals, with a strong focus on cancer treatments, cardiovascular medicines, and other specialist therapies. It also works on vaccines and other medicines, but its core role is making prescription products that address serious medical needs. The company sells mainly to healthcare providers and public health systems rather than to individual consumers. It makes money by selling its medicines through pharmacies, hospitals, distributors, and healthcare procurement channels, and in some cases by licensing drugs or sharing rights with other drugmakers. A large part of its value comes from research and development, since new patented medicines can generate sales for many years after approval. What makes Daiichi Sankyo different is that it sits near the high-value end of the drug business, where scientific research, regulatory approval, and long product development cycles matter more than factory scale. Its success depends on finding and bringing to market medicines that doctors trust for specific diseases, especially in oncology and other specialty areas. That gives it a business model tied closely to innovation, patent protection, and relationships with the medical system.
Daiichi Sankyo is a Japanese pharmaceutical company that discovers, develops, manufactures, and sells prescription medicines. Its business is built around branded drugs used by doctors and hospitals, with a strong focus on cancer treatments, cardiovascular medicines, and other specialist therapies. It also works on vaccines and other medicines, but its core role is making prescription products that address serious medical needs.
The company sells mainly to healthcare providers and public health systems rather than to individual consumers. It makes money by selling its medicines through pharmacies, hospitals, distributors, and healthcare procurement channels, and in some cases by licensing drugs or sharing rights with other drugmakers. A large part of its value comes from research and development, since new patented medicines can generate sales for many years after approval.
What makes Daiichi Sankyo different is that it sits near the high-value end of the drug business, where scientific research, regulatory approval, and long product development cycles matter more than factory scale. Its success depends on finding and bringing to market medicines that doctors trust for specific diseases, especially in oncology and other specialty areas. That gives it a business model tied closely to innovation, patent protection, and relationships with the medical system.
Strong Revenue Growth: Revenue rose 12.1% year-on-year to JPY 1,533.5 billion, driven by the continued growth of flagship oncology products ENHERTU and DATROWAY.
Profitability Mixed: Core operating profit increased 8.8% year-on-year, but operating profit fell 5.9% due to the absence of last year's temporary income and some negative impacts from one-off expenses.
Steady Oncology Expansion: ENHERTU and DATROWAY saw significant sales acceleration, new indication approvals, and expanded guideline recommendations worldwide.
Guidance Maintained: Management left full-year revenue and profit guidance unchanged from the October forecast, despite some product-specific adjustments.
R&D Pipeline Progress: Multiple regulatory filings and trial expansions for ENHERTU and DATROWAY were highlighted, with key data readouts and regulatory decisions expected in the coming fiscal year.
Portfolio Optimization: In-house development of the Claudin 6 ADC (DS-9606) was discontinued for strategic reasons, though the underlying technology remains promising.
CapEx Clarification: Planned capital expenditures are within previously announced commitments; no new or additional CapEx beyond prior disclosure.
Management
Sunao Manabe, D.V.M., Ph.D., is a prominent figure associated with Daiichi Sankyo Co., Ltd., a leading global pharmaceutical company headquartered in Japan. As a seasoned professional with extensive expertise in veterinary medicine and a doctorate in a related field, Dr. Manabe has significantly contributed to the advancement of innovative pharmaceutical products. At Daiichi Sankyo, Dr. Manabe has held various leadership roles, where he has been instrumental in overseeing research and development efforts, particularly focusing on drug discovery and development processes that align with the company's strategic goals. His background in veterinary medicine uniquely positions him to offer valuable insights into translational medicine and comparative models, enhancing the company's ability to develop effective therapeutic solutions. Dr. Manabe is known for his commitment to fostering innovation through scientific collaboration and has contributed to numerous initiatives that aim to address unmet medical needs. His work emphasizes the importance of integrating scientific research with practical applications to improve patient outcomes globally. Overall, Dr. Sunao Manabe's contributions to Daiichi Sankyo and the broader scientific community underscore his dedication to advancing healthcare through rigorous research and leadership in pharmaceutical development.
At Daiichi Sankyo, Dr. Manabe has held various leadership roles, where he has been instrumental in overseeing research and development efforts, particularly focusing on drug discovery and development processes that align with the company's strategic goals. His background in veterinary medicine uniquely positions him to offer valuable insights into translational medicine and comparative models, enhancing the company's ability to develop effective therapeutic solutions.
Dr. Manabe is known for his commitment to fostering innovation through scientific collaboration and has contributed to numerous initiatives that aim to address unmet medical needs. His work emphasizes the importance of integrating scientific research with practical applications to improve patient outcomes globally.
Overall, Dr. Sunao Manabe's contributions to Daiichi Sankyo and the broader scientific community underscore his dedication to advancing healthcare through rigorous research and leadership in pharmaceutical development.
Hiroyuki Okuzawa is a notable executive at Daiichi Sankyo Co., Ltd., a global pharmaceutical company based in Japan. As a high-ranking officer within the organization, Okuzawa has significantly contributed to the company's strategic and operational initiatives, leveraging his expertise in the pharmaceutical industry. He plays a crucial role in steering the company's global strategies, focusing on innovative research and development to enhance their competitive edge in the market. His leadership is instrumental in driving the company's mission of creating new pharmaceuticals to improve patient outcomes worldwide. His work often involves collaborations across various sectors within the company, ensuring the delivery of effective healthcare solutions and the successful execution of corporate goals.
Takashi Fukuoka, D.V.M., Ph.D., is a prominent figure in the pharmaceutical industry, particularly known for his role at Daiichi Sankyo Co., Ltd., a leading global pharmaceutical company based in Japan. With a strong background in veterinary medicine and a Ph.D., Dr. Fukuoka has contributed significantly to the field through his extensive research and leadership. At Daiichi Sankyo, Dr. Fukuoka has held various important positions that have leveraged his expertise in drug discovery and development. He plays a crucial role in advancing the company's research and development efforts, leading teams focused on creating new medical therapies and solutions. His work is vital in ensuring that Daiichi Sankyo remains at the forefront of pharmacological innovation, addressing unmet medical needs across various therapeutic areas. Dr. Fukuoka's contributions extend beyond his technical expertise, as he is also involved in strategic planning and decision-making processes within the company. His efforts help guide Daiichi Sankyo's mission to deliver innovative pharmaceuticals that improve patient health and quality of life globally.
At Daiichi Sankyo, Dr. Fukuoka has held various important positions that have leveraged his expertise in drug discovery and development. He plays a crucial role in advancing the company's research and development efforts, leading teams focused on creating new medical therapies and solutions. His work is vital in ensuring that Daiichi Sankyo remains at the forefront of pharmacological innovation, addressing unmet medical needs across various therapeutic areas.
Dr. Fukuoka's contributions extend beyond his technical expertise, as he is also involved in strategic planning and decision-making processes within the company. His efforts help guide Daiichi Sankyo's mission to deliver innovative pharmaceuticals that improve patient health and quality of life globally.
Dr. Shoji Hirashima is a respected figure in the pharmaceutical industry, particularly known for his contributions to Daiichi Sankyo Co., Ltd., a leading global pharmaceutical company based in Japan. Daiichi Sankyo is renowned for its focus on innovative research and development, particularly in the areas of oncology, cardiovascular diseases, and vaccines. Dr. Hirashima has played a key role in the company's research and development initiatives, often focusing on integrating scientific expertise and innovative approaches to create impactful medical solutions. His work involves overseeing clinical development, addressing unmet medical needs, and contributing to Daiichi Sankyo's strategic goals in delivering transformative therapies. His contributions extend to collaborations with academic institutions and other pharmaceutical entities, aiming to foster advancements in medical treatments and improve patient outcomes globally. As a leader within Daiichi Sankyo, Dr. Hirashima is instrumental in guiding both the scientific and operational aspects of the company's R&D endeavors. His work continues to influence the future direction of the pharmaceutical industry.
Dr. Hirashima has played a key role in the company's research and development initiatives, often focusing on integrating scientific expertise and innovative approaches to create impactful medical solutions. His work involves overseeing clinical development, addressing unmet medical needs, and contributing to Daiichi Sankyo's strategic goals in delivering transformative therapies.
His contributions extend to collaborations with academic institutions and other pharmaceutical entities, aiming to foster advancements in medical treatments and improve patient outcomes globally. As a leader within Daiichi Sankyo, Dr. Hirashima is instrumental in guiding both the scientific and operational aspects of the company's R&D endeavors. His work continues to influence the future direction of the pharmaceutical industry.
Koji Ogawa is a notable executive associated with Daiichi Sankyo Co., Ltd., a prominent global pharmaceutical company headquartered in Tokyo, Japan. As an executive leader, Ogawa has played a significant role in shaping the strategic direction and operational success of the company. Daiichi Sankyo is renowned for its innovative approach to healthcare, focusing on the research and development of novel therapies and pharmaceuticals to address unmet medical needs. While detailed personal information on Koji Ogawa, such as his educational background and prior career achievements, might be limited, his contributions to Daiichi Sankyo are part of the company's continued efforts in areas like oncology, cardiovascular medicine, and vaccine development. The company is committed to providing innovative and life-changing treatments, with executives like Ogawa involved in managing its expansive global operations and ensuring the company's adherence to its mission and values. In his role, Mr. Ogawa would typically be involved in high-level decision-making processes, corporate governance, and strategic partnerships, helping steer Daiichi Sankyo towards long-term growth and sustainability in the competitive pharmaceutical industry.
While detailed personal information on Koji Ogawa, such as his educational background and prior career achievements, might be limited, his contributions to Daiichi Sankyo are part of the company's continued efforts in areas like oncology, cardiovascular medicine, and vaccine development. The company is committed to providing innovative and life-changing treatments, with executives like Ogawa involved in managing its expansive global operations and ensuring the company's adherence to its mission and values.
In his role, Mr. Ogawa would typically be involved in high-level decision-making processes, corporate governance, and strategic partnerships, helping steer Daiichi Sankyo towards long-term growth and sustainability in the competitive pharmaceutical industry.
Tomohiro Kodama is an executive at Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Tokyo, Japan. As a member of the leadership team, Kodama has played a significant role in shaping the company's strategies and operations. Daiichi Sankyo is known for its research and development in the pharmaceutical industry, focusing on oncology, cardiovascular diseases, and other critical therapeutic areas. Kodama's work at Daiichi Sankyo involves overseeing strategic initiatives that align with the company's mission to enhance healthcare and improve the quality of life for patients worldwide. His contributions have been instrumental in advancing the company's pipeline of innovative drugs, particularly in oncology, where Daiichi Sankyo has made significant strides. With a commitment to innovation and excellence, Kodama and his team at Daiichi Sankyo continue to explore new opportunities to drive growth and deliver impactful healthcare solutions globally. His leadership and vision have helped maintain the company's reputation as a forward-thinking and socially responsible organization in the pharmaceutical sector.
Kodama's work at Daiichi Sankyo involves overseeing strategic initiatives that align with the company's mission to enhance healthcare and improve the quality of life for patients worldwide. His contributions have been instrumental in advancing the company's pipeline of innovative drugs, particularly in oncology, where Daiichi Sankyo has made significant strides.
With a commitment to innovation and excellence, Kodama and his team at Daiichi Sankyo continue to explore new opportunities to drive growth and deliver impactful healthcare solutions globally. His leadership and vision have helped maintain the company's reputation as a forward-thinking and socially responsible organization in the pharmaceutical sector.
Hiroto Kashiwase is an executive officer at Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Tokyo, Japan. He serves as an Executive Officer and is responsible for overseeing supply chain and manufacturing activities within the company. Kashiwase has played a significant role in ensuring the efficiency and reliability of Daiichi Sankyo's production and distribution networks. His work helps facilitate the company's mission to provide innovative and high-quality pharmaceutical products to improve patient care worldwide. Under his leadership, the company has strengthened its manufacturing capabilities and enhanced its supply chain strategies, contributing to its competitive position in the global market.
Naoto Tsukaguchi is the Executive Officer and Global Head of Corporate Communications at Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. In his role, Tsukaguchi is responsible for overseeing the company's communication strategies on a global scale, which includes managing its public relations, internal communications, and media outreach. He plays a key part in shaping the company's corporate image and ensuring consistent and effective messaging across all markets. With extensive experience in communication within the pharmaceutical industry, Tsukaguchi contributes significantly to enhancing the company's reputation and stakeholder engagement. His leadership is pivotal in maintaining transparency and promoting the innovations and developments Daiichi Sankyo brings to healthcare.
As of the latest available information, Kentaro Asakura is an executive officer at Daiichi Sankyo Co., Ltd., a global pharmaceutical company based in Japan. Daiichi Sankyo is known for its focus on innovative research and development in therapeutic areas such as oncology, cardiovascular medicine, and infectious diseases. Kentaro Asakura holds a significant role within the company, contributing to its strategic leadership and operational management. His responsibilities likely involve overseeing various aspects of the company's business operations and guiding its strategic direction to enhance global competitiveness and sustain growth in the pharmaceutical industry. Due to the company's commitment to medical innovation and patient care, Asakura's work would be pivotal in advancing Daiichi Sankyo's mission to address unmet medical needs and improve healthcare outcomes worldwide. His leadership is crucial in navigating the regulatory, commercial, and scientific challenges inherent in the pharmaceutical sector.
Kentaro Asakura holds a significant role within the company, contributing to its strategic leadership and operational management. His responsibilities likely involve overseeing various aspects of the company's business operations and guiding its strategic direction to enhance global competitiveness and sustain growth in the pharmaceutical industry.
Due to the company's commitment to medical innovation and patient care, Asakura's work would be pivotal in advancing Daiichi Sankyo's mission to address unmet medical needs and improve healthcare outcomes worldwide. His leadership is crucial in navigating the regulatory, commercial, and scientific challenges inherent in the pharmaceutical sector.
